{"id":"ffp-hdmp-rituximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (opportunistic or bacterial)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Immunosuppression-related complications"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FFP provides clotting factors and immunomodulatory proteins, HDMP is a potent corticosteroid that suppresses immune activation and inflammation, and rituximab is a monoclonal antibody targeting CD20 on B cells to deplete the B-cell population. Together, this regimen addresses both the coagulation abnormalities and pathogenic autoimmune mechanisms in severe systemic diseases.","oneSentence":"This combination therapy uses fresh frozen plasma (FFP) and high-dose methylprednisolone (HDMP) with rituximab to suppress autoimmune responses by depleting B cells and reducing inflammatory mediators.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:30.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe autoimmune or thrombotic microangiopathy conditions (specific indication not publicly detailed in available literature)"}]},"trialDetails":[{"nctId":"NCT01670812","phase":"PHASE3","title":"Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2012-01","conditions":"Chronic Lymphocytic Leukemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fresh frozen plasma","methylprednisolone","rituximab"],"phase":"phase_3","status":"active","brandName":"FFP+HDMP+Rituximab","genericName":"FFP+HDMP+Rituximab","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses fresh frozen plasma (FFP) and high-dose methylprednisolone (HDMP) with rituximab to suppress autoimmune responses by depleting B cells and reducing inflammatory mediators. Used for Severe autoimmune or thrombotic microangiopathy conditions (specific indication not publicly detailed in available literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":8,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}